Timing of treatment of smoldering myeloma: early treatment

Blood Adv. 2018 Nov 13;2(21):3045-3049. doi: 10.1182/bloodadvances.2018021220.

Abstract

This article has a companion Counterpoint by Kumar.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Disease Progression
  • Humans
  • Myeloma Proteins / analysis
  • Proportional Hazards Models
  • Quality of Life
  • Risk Factors
  • Smoldering Multiple Myeloma / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Myeloma Proteins